Breaking News
Get 40% Off 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolios
Close

Breaking News

Initial jobless claims dip to 222,000 last week, but still above estimates

Sk Biopharmaceuticals Co Ltd (326030)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
89,600 +2100    +2.40%
02:49:06 - Closed. Currency in KRW ( Disclaimer )
Type:  Equity
Market:  South Korea
ISIN:  KR7326030004 
  • Volume: 67,439
  • Bid/Ask: 89,500 / 89,600
  • Day's Range: 88,800 - 90,200
Sk Biopharma 89,600 +2100 +2.40%

326030 Balance Sheet

 
Featured here, the Balance Sheet for Sk Biopharmaceuticals Co Ltd, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 488722.24 501050.57 435465.95 456145.2
Cash and Short Term Investments 241118.44 272871.75 222887.18 255011.31
Cash - - - -
Cash & Equivalents 239700.04 271392.41 106443.05 103577.08
Short Term Investments 1418.39 1479.34 116444.14 151434.24
Total Receivables, Net 113642.4 94454.02 82393.68 72113.64
Accounts Receivables - Trade, Net 111000.94 92468.9 78013.93 68726.03
Total Inventory 102525.49 107655.73 107736.45 104354.82
Prepaid Expenses 25897.77 23021.91 20172.29 19824.46
Other Current Assets, Total 5538.14 3047.17 2276.36 4840.98
Total Assets 723170.58 751052.3 631160.1 656029.44
Property/Plant/Equipment, Total - Net 47753.14 50027.93 16489.72 18388.47
Property/Plant/Equipment, Total - Gross 102351.84 102831.38 65035.6 65674.53
Accumulated Depreciation, Total -54598.7 -52803.45 -48545.88 -47286.06
Goodwill, Net 3391.91 4215.43 - -
Intangibles, Net 14542.43 15524.97 16723.91 17304.07
Long Term Investments 104091.3 119127.82 118814.99 123265.5
Note Receivable - Long Term 2641.46 1985.12 4379.74 3387.61
Other Long Term Assets, Total 10771.08 8008.57 7483.86 8273.86
Other Assets, Total 49738.1 70825.22 180244.93 221168.72
Total Current Liabilities 241618.59 254419.13 195124.92 186225.19
Accounts Payable 2345.8 2736.35 10602.35 13998.01
Payable/Accrued - - - -
Accrued Expenses 71330.88 63837.48 58313.78 52071.95
Notes Payable/Short Term Debt 50000 50000 25000 25000
Current Port. of LT Debt/Capital Leases 7060.82 5754.09 5457.11 5807.76
Other Current liabilities, Total 110881.09 132091.21 95751.67 89347.47
Total Liabilities 402219.38 428561.7 339428.99 339779.6
Total Long Term Debt 120989.23 125192.42 125180.29 125635.28
Long Term Debt 94484.3 96395.6 120291.6 119981.1
Capital Lease Obligations 26504.93 28796.82 4888.69 5654.18
Deferred Income Tax 1908.96 2668.76 - -
Minority Interest 37264.82 36880.34 - -
Other Liabilities, Total -94046.52 -86994.54 -5876.22 -67061.96
Total Equity 320951.19 322490.6 291731.11 316249.83
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 39156.62 39156.62 39156.62 39156.62
Additional Paid-In Capital 1084847.58 1084847.58 1084847.58 1084847.58
Retained Earnings (Accumulated Deficit) -861560.73 -867329.74 -853518.37 -830392.91
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 58507.72 65816.13 21245.27 22638.53
Total Liabilities & Shareholders' Equity 723170.58 751052.3 631160.1 656029.44
Total Common Shares Outstanding 78.31 78.31 78.31 78.31
Total Preferred Shares Outstanding - - - -
* In Millions of KRW (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

326030 Comments

Write your thoughts about Sk Biopharmaceuticals Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email